New immune combo aims to slow bile duct cancer
NCT ID NCT04910386
First seen Apr 13, 2026 · Last updated Apr 24, 2026 · Updated 2 times
Summary
This study tests whether adding the immunotherapy drug envafolimab to standard chemotherapy (gemcitabine plus cisplatin) helps people with advanced bile duct or gallbladder cancer live longer without their cancer growing. About 126 adults who have not had prior treatment for advanced disease will be randomly assigned to receive either the combo or chemo alone. The main goal is to see if the combo delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.